Literature DB >> 29086614

The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group.

Harneet Hundal1, Rachel Lister2, Nicole Evans2, Angus Antley3, Amir Englund1, Robin M Murray1, Daniel Freeman2, Paul D Morrison1.   

Abstract

BACKGROUND: Previous studies have suggested that cannabidiol has anxiolytic and antipsychotic properties, raising hopes that cannabidiol will translate to the psychiatric clinic. Cannabidiol may be particularly useful for anxiety and paranoia in those at-risk of major mental illness.
METHODS: Immersion in a controlled 3D virtual-reality scenario was used to assay persecutory ideation and anxiety in a sample of non-clinical volunteers ( n=32) pre-selected for high paranoid traits. Participants were randomised to receive oral cannabidiol (600 mg) or placebo 130 min prior to entering virtual-reality. Well-validated rating scales were used to assay persecutory thinking and anxiety. Salivary cortisol concentration, heart rate and blood pressure were measured over the course of the experimental session.
RESULTS: Immersion in the virtual-reality session elicited anxiety as indexed by the Beck's anxiety inventory ( p<0.005), and increased cortisol concentration ( p=0.05), heart rate ( p<0.05) and systolic blood pressure ( p<0.05). However, cannabidiol had no impact upon any of these effects, except for a strong trend to increase anxiety ( p=0.09). Cannabidiol had no effect on persecutory ideation as assayed by the Community Assessment of Psychic Experiences questionnaire or the State Social Paranoia Scale.
CONCLUSIONS: In contrast to previous studies, there was no evidence of any benefits of cannabidiol on anxiety or persecutory ideation in healthy volunteers with high trait paranoia. However, a larger sample will be required for a definitive study.

Entities:  

Keywords:  Cannabidiol; anxiety; at risk mental state; paranoia; psychosis

Mesh:

Substances:

Year:  2017        PMID: 29086614     DOI: 10.1177/0269881117737400

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  11 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

2.  Herbs as an Active Ingredient in Sport: Availability and Information on the Internet.

Authors:  Juan F Garcia; Soledad Arribalzaga; Raquel Díez; Cristina Lopez; M Nelida Fernandez; Juan J Garcia; M Jose Diez; Jesús Seco-Calvo; Matilde Sierra; Ana M Sahagún
Journal:  Nutrients       Date:  2022-07-04       Impact factor: 6.706

3.  The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials.

Authors:  Yuni Tang; Kolbi L Tonkovich; Toni Marie Rudisill
Journal:  Pharmaceut Med       Date:  2022-10-21

4.  Statement on safety of cannabidiol as a novel food: data gaps and uncertainties.

Authors:  Dominique Turck; Torsten Bohn; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Pelaez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; Thomas Frenzel; Marina Heinonen; Rosangela Marchelli; Monika Neuhäuser-Berthold; Morten Poulsen; Miguel Prieto Maradona; Josef Rudolf Schlatter; Viviana Trezza; Henk van Loveren; Océane Albert; Céline Dumas; Andrea Germini; Wolfgang Gelbmann; Georges Kass; Eirini Kouloura; Estefania Noriega Fernandez; Annamaria Rossi; Helle Katrine Knutsen
Journal:  EFSA J       Date:  2022-06-07

5.  Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies.

Authors:  Dennis J Sholler; Lauren Schoene; Tory R Spindle
Journal:  Curr Addict Rep       Date:  2020-07-25

6.  The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study.

Authors:  Michael A P Bloomfield; Yumeya Yamamori; Chandni Hindocha; Augustus P M Jones; Jocelyn L L Yim; Hannah R Walker; Ben Statton; Matthew B Wall; Rachel H Lees; Oliver D Howes; Valerie H Curran; Jonathan P Roiser; Tom P Freeman
Journal:  Psychopharmacology (Berl)       Date:  2022-04-21       Impact factor: 4.415

Review 7.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.

Authors:  María S García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Amaya Austrich-Olivares; Francisco Sala; Jorge Manzanares
Journal:  Biomolecules       Date:  2020-11-19

Review 8.  Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Authors:  Ainhoa Bilbao; Rainer Spanagel
Journal:  BMC Med       Date:  2022-08-19       Impact factor: 11.150

9.  Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic.

Authors:  Lucile Rapin; Rihab Gamaoun; Cynthia El Hage; Maria Fernanda Arboleda; Erin Prosk
Journal:  J Cannabis Res       Date:  2021-06-23

10.  The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers.

Authors:  C Hindocha; T P Freeman; M Grabski; H Crudgington; A C Davies; J B Stroud; R K Das; W Lawn; C J A Morgan; H V Curran
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.